Qu Biologics

Site Specific Immunomodulators, innate immunity, immunotherapy

trainingimmunotherapy

qubiologics.com·4475 Wayburne Drive, Suite 305 Burnaby, B.C., Canada, V5G 4X4·$12M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-9JRA

Summary · Eternal Search editorial

Qu Biologics Site Specific Immunomodulators, innate immunity, immunotherapy

Qu Biologics is a private clinical-stage biotech developing site-specific immunomodulators made from inactivated microbial species that are claimed to direct innate immune activity to particular organs. The strongest independent evidence here is mixed but nontrivial: a randomized proof-of-concept Crohn’s disease trial reported tolerability and modest efficacy signals, while multiple peer-reviewed mouse studies support organ-specific and disease-specific immune effects in gut, lung, and fatty liver models. The core risk is that much of the broader oncology, aging, senescence, and platform narrative remains company-authored, preclinical, or patent-based rather than decisively validated in humans.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite12

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Qu Biologics — Translational · Bottom quartile. Derived deterministically from 20 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (6 programs at…

Source: Deterministic

At a glance

Webqubiologics.com

HQ4475 Wayburne Drive, Suite 305 Burnaby, B.C., Canada, V5G 4X4

Publications

18 on file

012026Postbiotic gut bacteria site-specific immunomodulators improve liver steatosis, inflammation, and fibrosis in obese mice with MASLD.American journal of physiology. Endocrinology and metabolism→022020Distinct inactivated bacterial-based immune modulators vary in their therapeutic efficacies for treating disease based on the organ site of pathology—→032020Distinct inactivated bacterial-based immune modulators vary in their therapeutic efficacies for treating disease based on the organ site of pathologyScientific Reports→042019Novel Microbial-Based Immunotherapy Approach for Crohn’s Disease—→052019Novel Microbial-Based Immunotherapy Approach for Crohn's DiseaseFrontiers in Medicine→062019The right microbial stimulus can direct innate immune effector cells to specific organ sites to clear pathologybioRxiv (Cold Spring Harbor Laboratory)→072019Novel Microbial-Based Immunotherapy Approach for Crohn’s Disease—→082018Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis—→092018Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis.—→102017Attenuating immune pathology using a microbial-based intervention in a mouse model of cigarette smoke-induced lung inflammation.—→112017Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.—→122017Attenuating immune pathology using a microbial-based intervention in a mouse model of cigarette smoke-induced lung inflammationRespiratory Research→132016A novel microbe-based treatment that attenuates the inflammatory profile in a mouse model of allergic airway disease.—→142015Site-Specific Immunomodulator: A Novel Treatment for Crohn’s Disease—→152015Site-Specific Immunomodulator: A Novel Treatment for Crohn’s DiseaseGastroenterology Research and Practice→16—Attenuating immune pathology using a microbial-based intervention in a mouse model of cigarette smoke-induced lung inflammation—→17—Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy—→18—A novel microbe-based treatment that attenuates the inflammatory profile in a mouse model of allergic airway disease—→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Qu Biologics

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.